1.3 Diabetes Mellitus in Pregnancy

Classification and Pathophysiology of Diabetes in Pregnancy

Carbohydrate intolerance is one of the most common medical complications of pregnancy, affecting approximately 7% to 10% of all gestations. Diabetes in pregnancy is broadly classified into two major categories:

1. Pre-existing (Pregestational) Diabetes: Type 1 diabetes mellitus (autoimmune beta-cell destruction resulting in absolute insulin deficiency) or Type 2 diabetes mellitus (progressive insulin secretory defect on the background of chronic insulin resistance) diagnosed prior to conception or during the first trimester (HbA1c ≥6.5% or fasting plasma glucose ≥126 mg/dL).
2. Gestational Diabetes Mellitus (GDM): Carbohydrate intolerance with onset or first recognition during the second or third trimester of pregnancy. GDM is further subclassified into:
   • Class A1 (Diet-Controlled): Normal fasting glucose (<95 mg/dL) and postprandial glucose levels maintained strictly through medical nutrition therapy (MNT) and physical activity.
   • Class A2 (Medication-Requiring): Abnormal fasting or postprandial glucose levels requiring pharmacotherapy (insulin or oral hypoglycemics) to achieve euglycemia.

Endocrine Physiology of Pregnancy

Normal pregnancy is characterized by profound metabolic adaptations designed to ensure a constant supply of glucose and amino acids to the developing fetus:

• First Trimester (Anabolic Phase): Elevated maternal estrogen and progesterone stimulate maternal pancreatic beta-cell hyperplasia, increasing insulin sensitivity and glycogen storage. Maternal fasting glucose levels are lower than in non-pregnant states (often 70–80 mg/dL).
• Second and Third Trimesters (Catabolic / Diabetogenic Phase): As the placenta expands, it secretes increasing quantities of counter-regulatory anti-insulin hormones, primarily Human Placental Lactogen (hPL / Human Chorionic Somatomammotropin), human placental growth hormone (hPGH), progesterone, cortisol, prolactin, and tumor necrosis factor-alpha (TNF-α). These hormones induce peripheral insulin resistance (a 50% to 60% decrease in insulin sensitivity), peaking between 24 and 28 weeks of gestation. In normal pregnancy, maternal pancreatic beta cells compensate by increasing insulin secretion 2- to 3-fold. In gestational diabetes, maternal beta cells fail to overcome this physiologic resistance, leading to maternal hyperglycemia.

+-------------------------------------------------------------------------------------------------------------------+
|                                    SCREENING & DIAGNOSTIC CRITERIA FOR GDM (24-28 WEEKS)                          |
+-------------------------------------------------------------------------------------------------------------------+
                                                         |
                                         [ 50g 1-Hour Non-Fasting GLT Screen ]
                                                         |
                 +---------------------------------------+---------------------------------------+
                 |                                                                               |
       [ Glucose <130-140 mg/dL ]                                                      [ Glucose ≥130-140 mg/dL ]
                 |                                                                               |
        [ Normal / Negative ]                                                  +-----------------+-----------------+
                                                                               |                                   |
                                                                     [ Glucose ≥200 mg/dL ]              [ Glucose 130-199 mg/dL ]
                                                                               |                                   |
                                                                   [ Diagnostic of GDM ]                 [ Perform 100g 3-Hour OGTT ]
                                                                   (No 3-hr OGTT needed)                   (Fasting overnight ≥8 hr)
                                                                                                                   |
+------------------------------------------------------------------------------------------------------------------+
| 100g 3-Hour OGTT Diagnostic Thresholds (≥2 Abnormal Values Required for Diagnosis)                              |
| ---------------------------------------------------------------------------------------------------------------- |
| Measurement Timepoint                 Carpenter-Coustan Criteria                  NDDG Criteria                  |
| Fasting                               ≥95 mg/dL (5.3 mmol/L)                      ≥105 mg/dL (5.8 mmol/L)        |
| 1-Hour Post-Load                      ≥180 mg/dL (10.0 mmol/L)                    ≥190 mg/dL (10.6 mmol/L)       |
| 2-Hour Post-Load                      ≥155 mg/dL (8.6 mmol/L)                     ≥165 mg/dL (9.2 mmol/L)        |
| 3-Hour Post-Load                      ≥140 mg/dL (7.8 mmol/L)                     ≥145 mg/dL (8.0 mmol/L)        |
+------------------------------------------------------------------------------------------------------------------+

---

Target Blood Glucose Levels and Antenatal Management

To minimize maternal and fetal complications, strict blood glucose targets are established for all pregnant women with pregestational or gestational diabetes:

Pharmacotherapy

• Insulin (First-Line Gold Standard): Insulin does NOT cross the placenta and is the drug of choice. Regimens typically combine intermediate/long-acting basal insulin (NPH, Insulin Detemir, Insulin Glargine) with rapid-acting prandial insulin (Insulin Lispro, Insulin Aspart) administered before meals.
• Oral Antihyperglycemic Agents (Second-Line):
  • Metformin: Crosses the placenta readily (fetal levels equal or exceed maternal levels). Associated with lower rates of maternal hypoglycemia and less gestational weight gain, but higher rates of preterm birth and unknown long-term offspring metabolic effects.
  • Glyburide (Sulfonylurea): Crosses the placenta; associated with higher rates of neonatal hypoglycemia, macrosomia, and hyperbilirubinemia compared to insulin.

---

Intrapartum Glycemic Control Protocol

Maternal hyperglycemia during labor stimulates the fetal pancreas to secrete massive amounts of insulin. Following delivery and sudden separation from the maternal glucose supply, the neonate's elevated circulating insulin levels induce rapid, severe rebound neonatal hypoglycemia.

Inpatient Intrapartum Nursing Protocol

1. Target Intrapartum Glycemic Range: Maintain maternal capillary blood glucose strictly between 70 and 110 mg/dL (or <120 mg/dL).
2. Monitoring Frequency: Measure capillary blood glucose every 1 hour during active labor or while on an IV insulin infusion (every 2 to 4 hours in early latent labor if diet-controlled).
3. Dual Infusion Setup (Insulin and Dextrose Lines):
   • Primary Line: 5% Dextrose in 0.9% Normal Saline ($D_5NS$) or 5% Dextrose in Lactated Ringer's ($D_5LR$) running at a constant rate of 100 to 125 mL/hour (provides 5–6 g glucose/hr for active uterine myometrial work).
   • Secondary Piggyback Line: Regular Human Insulin (100 units in 100 mL 0.9% Normal Saline = 1 unit/mL) connected to the lowest port via an automated smart infusion pump.

+-------------------------------------------------------------------------------------------------------------------+
|                         STANDARDIZED INTRAPARTUM IV REGULAR INSULIN TITRATION ALGORITHM                           |
+-------------------------------------------------------------------------------------------------------------------+
  Blood Glucose Level (mg/dL)     IV Insulin Infusion Rate (units/hr)       IV Fluid Maintenance Solution
  ---------------------------     -----------------------------------       -----------------------------
  <70 mg/dL                       0.0 units/hr (STOP infusion)              Increase D5W to 150 mL/hr; recheck in 30 min
  70 - 99 mg/dL                   0.0 units/hr (Hold infusion)              D5W or D5 1/2 NS at 100-125 mL/hr
  100 - 119 mg/dL                 0.5 units/hr                              D5 1/2 NS at 100 mL/hr
  120 - 139 mg/dL                 1.0 units/hr                              D5 1/2 NS at 100 mL/hr
  140 - 159 mg/dL                 1.5 units/hr                              Switch to Normal Saline (No Dextrose) @ 100 mL/hr
  160 - 179 mg/dL                 2.0 units/hr                              Normal Saline (No Dextrose) @ 100 mL/hr
  ≥180 mg/dL                      2.5 - 3.0 units/hr (Notify Provider)      Normal Saline (No Dextrose) @ 100 mL/hr
+-------------------------------------------------------------------------------------------------------------------+

---

Diabetic Ketoacidosis (DKA) in Pregnancy

Diabetic Ketoacidosis (DKA) is an extreme obstetric medical emergency carrying a maternal mortality of 1% to 3% and a fetal mortality rate of 15% to 35%. Pregnancy is an inherently ketogenic state due to accelerated starvation, increased lipolysis, reduced buffering capacity (physiologic respiratory alkalosis with low baseline bicarbonate [18–22 mEq/L]), and placental hormones.

Critical Clinical Pearl: Euglycemic DKA: In pregnant patients, DKA frequently develops at much lower blood glucose concentrations than in non-pregnant individuals—frequently presenting with blood glucose levels <200 mg/dL (and even <150 mg/dL). This occurs because of continuous transplacental glucose siphonage by the fetus and placenta, expanded maternal intravascular volume, and marked glycosuria from increased GFR.

Clinical Presentation and Diagnostic Criteria

• Triggers: Infection (chorioamnionitis, pyelonephritis, influenza), non-compliance or pump failure, beta-mimetic tocolytic therapy (terbutaline), antenatal corticosteroid administration (betamethasone), or vomiting/starvation.
• Signs & Symptoms: Nausea, vomiting, abdominal pain, Kussmaul respirations (rapid, deep breathing to blow off $CO_2$), fruity acetone breath odor, altered sensorium, and maternal tachycardia.
• Laboratory Profile:
  • Arterial pH <7.30 (or venous pH <7.25)
  • Serum Bicarbonate ($HCO_3^-$) <15 mEq/L
  • Elevated Anion Gap: $[Na^+] - ([Cl^-] + [HCO_3^-]) > 12\text{ mEq/L}$
  • Positive serum and urine ketones (elevated beta-hydroxybutyrate >3.0 mmol/L)

Inpatient DKA Resuscitation Protocol

+-------------------------------------------------------------------------------------------------------------------+
|                                      STEP-BY-STEP INTRAPARTUM DKA PROTOCOL                                        |
+-------------------------------------------------------------------------------------------------------------------+
                                                         |
                                       [ 1. AGGRESSIVE FLUID RESUSCITATION ]
                                       - 1st Hour: 1.0 to 2.0 Liters of 0.9% Normal Saline
                                       - 2nd to 4th Hours: 250 to 500 mL/hr of 0.45% or 0.9% Normal Saline
                                       - Switch to D5 1/2 NS when Blood Glucose reaches ≤200 mg/dL
                                                         |
                                       [ 2. INTRAVENOUS REGULAR INSULIN INFUSION ]
                                       - Initial IV Bolus: 0.1 units/kg (optional)
                                       - Continuous IV Infusion: 0.1 units/kg/hour
                                       - Goal: Reduce glucose by 50 to 75 mg/dL per hour
                                       - Maintain insulin infusion until anion gap closes and acidosis resolves
                                                         |
                                       [ 3. POTASSIUM REPLACEMENT ]
                                       - If K+ >5.2 mEq/L: Do NOT give potassium; check q2h
                                       - If K+ 3.5 - 5.2 mEq/L: Add 20 - 30 mEq KCl per liter of IV fluid once urine output verified
                                       - If K+ <3.5 mEq/L: HOLD insulin; give 20 - 40 mEq/hr until K+ >3.5 mEq/L (prevents cardiac arrest)
                                                         |
                                       [ 4. FETAL SURVEILLANCE & RESUSCITATION ]
                                       - Expect transient Category II/III patterns (late decelerations, minimal variability)
                                       - DO NOT perform emergency delivery during active ketoacidosis
                                       - FHR tracing recovers as maternal acidosis and volume deficits normalize
+-------------------------------------------------------------------------------------------------------------------+

---

Maternal, Fetal, and Neonatal Complications

+-------------------------------------------------------------------------------------------------------------------+
|                                    PATHOPHYSIOLOGIC EFFECTS OF MATERNAL HYPERGLYCEMIA                             |
+-------------------------------------------------------------------------------------------------------------------+
  MATERNAL HYPERGLYCEMIA                  FETAL CONSEQUENCES                     NEONATAL MORBIDITIES
  ---------------------                  ------------------                     --------------------
  Glucose crosses placenta                Fetal Hyperglycemia                    Neonatal Hypoglycemia (<40 mg/dL)
  (Insulin does NOT cross)         -->    Fetal Pancreatic Hyperplasia    -->    Respiratory Distress Syndrome (RDS)
                                          Excessive Fetal Insulin                Polycythemia & Hyperbilirubinemia
                                          Asymmetric Macrosomia (>4500g)         Hypocalcemia & Hypomagnesemia
                                          Polyhydramnios (osmotic diuresis)      Hypertrophic Cardiomyopathy
+-------------------------------------------------------------------------------------------------------------------+

Maternal Complications

• Preeclampsia and gestational hypertension (3- to 4-fold increased risk).
• Diabetic retinopathy progression and worsening diabetic nephropathy.
• Polyhydramnios (Amniotic Fluid Index [AFI] ≥24 cm or Single Deepest Pocket [SDP] ≥8 cm) secondary to fetal polyuria, increasing the risk of preterm labor, placental abruption, and postpartum hemorrhage.
• Operative vaginal delivery, severe perineal lacerations (3rd/4th degree), and primary cesarean delivery.

Fetal Malformations and Organopathy

• Congenital Anomalies (Unique to Pregestational Diabetes with Periconceptional Hyperglycemia):
  • Caudal Regression Syndrome (Sacral Agenesis): 200-fold increase; highly specific for pregestational diabetes.
  • Congenital Heart Defects: Transposition of the great vessels, Ventricular Septal Defect (VSD), coarctation of the aorta.
  • Central Nervous System: Anencephaly, spina bifida, hydrocephalus.
• Fetal Growth Derangements:
  • Asymmetric Macrosomia (Pedersen Hypothesis): Excess maternal glucose traverses the placenta via facilitated diffusion. The fetal pancreas responds with beta-cell hyperplasia and hyperinsulinemia. Fetal insulin acts as a potent growth hormone, stimulating lipogenesis and protein synthesis, resulting in disproportionate fat deposition over the shoulders and torso (shoulder-to-head disproportion), predisposing to shoulder dystocia.
• Delayed Fetal Lung Maturity: Fetal hyperinsulinemia directly blocks the inductive actions of cortisol on alveolar type II pneumocytes, inhibiting the transcription of surfactant proteins (SP-A, SP-B) and delaying lecithin synthesis. Consequently, infants of diabetic mothers are at high risk for Respiratory Distress Syndrome (RDS) even at term (37–38 weeks).

---

Delivery Timing and Postpartum Management

• Delivery Timing Guidelines:
  • GDM Class A1 (Diet-controlled): Expectant management with planned delivery at 39 0/7 to 40 6/7 weeks.
  • GDM Class A2 (Medication-requiring): Planned delivery at 39 0/7 to 39 6/7 weeks.
  • Poorly Controlled GDM / Pregestational Diabetes with Vascular Disease: Planned delivery at 36 0/7 to 38 6/7 weeks.
  • Estimated Fetal Weight (EFW) Threshold for Cesarean Delivery: Offer elective cesarean delivery if EFW is >4,500 grams in diabetic gravidas (compared to >5,000 g in non-diabetic gravidas) to prevent catastrophic shoulder dystocia and brachial plexus injury.
• Postpartum Insulin Management:
  • Following the expulsion of the placenta, circulating levels of hPL, progesterone, and cortisol drop precipitously within hours, abruptly reversing insulin resistance.
  • In patients with GDM: Discontinue all insulin and oral hypoglycemics immediately upon delivery; monitor postpartum fasting glucose.
  • In patients with Type 1 Diabetes: Immediately reduce baseline pre-pregnancy insulin doses by 50% or initiate a low-dose subcutaneous sliding scale to prevent severe postpartum hypoglycemia.
  • Postpartum Screening for GDM: Perform a 75g 2-hour oral glucose tolerance test (OGTT) at 4 to 12 weeks postpartum to screen for persistent pre-diabetes or overt Type 2 diabetes.